---
figid: PMC9570456__ijms-23-11835-g002
pmcid: PMC9570456
image_filename: ijms-23-11835-g002.jpg
figure_link: /pmc/articles/PMC9570456/figure/ijms-23-11835-f002/
number: Figure 2
figure_title: ''
caption: ATP and adenosine metabolism and signaling in cancer and schizophrenia. Perturbations
  in extracellular adenosine generating pathways are implicated in schizophrenia (green
  arrows) and cancer (red arrows). Differential purinergic (P1 and P2 receptors) receptor
  expression is reported in schizophrenia and cancer. ADA adenosine deaminase, ADK
  adenosine kinase, ADO adenosine, ATP adenosine triphosphate, ADP adenosine diphosphate
  AMP adenosine monophosphate, ENTPD ectonucleoside triphosphate diphosphohydrolases,
  NT5E ecto-5â€²nucleotidase. Generated in Biorender.
article_title: 'Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer
  a Pathway to Treatment?.'
citation: Abdul-Rizaq Hamoud, et al. Int J Mol Sci. 2022 Oct;23(19):11835.
year: '2022'

doi: 10.3390/ijms231911835
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- schizophrenia
- cancer
- adenosine
- purinergic signaling
- epidemiology

---
